Quadrant Biosciences works with top academic institutions, medical researchers and engineers to translate breakthrough findings into thoughtfully developed and scientifically sound assessment applications.
Our evolutionary advancements in brain health assessment, autism and Parkinson’s detection, will have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions going forward. Supported through private and state funding, one of these key technologies, ClearEdge, is currently available in the market and the others are slated for a 2018 release.
Validation of a salivary RNA test for childhood autism spectrum disorder
Read about the groundbreaking research supporting our novel, non-invasive saliva test that accurately distinguishes children with ASD from their neurotypical peers, as well as children with other non-autistic developmental delays.
HOF Players Foundation and Quadrant Biosciences Partner to Address Former Football Players’ Health Concerns
New brain health assessment toolkit to track players’ brain health over time
Read the Press Release
Understanding microRNA: These tiny keys could unlock a treasure trove of medical knowledge
Dr. Frank Middleton is featured in the most recent Upstate Medical University Health magazine!
Read the article in Upstate Health here